Roche scraps 5 trials: Alzheimer’s ‘High Risk’

By |2022-07-21T09:03:54-07:00July 21st, 2022|Brief Bulletins from the Field, We Know Psychiatry|

In a continuation of bad news for investigative Alzheimer's drugs, Roche has halted five early and midstage trials covering a range of therapeutic categories, including Alzheimer's drugs. The Swiss pharma admits that two of its most exciting prospects remain high-risk. The drugmaker also confirmed it had removed a phase 2 [...]

Sage, Biogen show good results on zuranolone phase 3 depression trial

By |2022-02-16T10:00:01-08:00February 16th, 2022|Brief Bulletins from the Field, We Know Psychiatry|

Sage and Biogen’s depression drug quickly relieved symptoms of depression in a phase 3 trial, but the readout did little to quell concerns about the med’s durability of effect, an issue that investors and analysts have been concerned about, according to a blog published today on Fierce Biotech. In the [...]

Bipolar spectrum disorder masquerading as treatment resistant unipolar depression

By |2022-02-15T08:08:52-08:00February 15th, 2022|Brief Bulletins from the Field, We Know Psychiatry|

We are frequently consulted by patients with treatment resistant depression (TRD).Reference Fogelson and Leuchter1 Many of these patients have never met criteria for a manic episode so they are not diagnosed with bipolar disorder (BPD). Consequently, they have undergone trials of antidepressants with or without augmentation therapies without success.Reference Perlis, Uher [...]

Dementia-related psychosis and the potential role for pimavanserin

By |2022-02-15T08:04:00-08:00February 15th, 2022|Brief Bulletins from the Field, We Know Psychiatry|

No pharmacological agents are approved by the U.S. Food and Drug Administration (FDA) to treat dementia-related psychosis (DRP). Pimavanserin, an atypical antipsychotic that acts as a selective serotonin inverse agonist/antagonist at 5-HT2A receptors (and to a lesser extent, at 5-HT2c receptors), is the only FDA-approved treatment for hallucinations and delusions associated with [...]

C.D.C. Proposes New Guidelines for Opioid Use

By |2022-02-10T07:37:32-08:00February 10th, 2022|Brief Bulletins from the Field, We Know Psychiatry|

The federal government on Thursday proposed new guidelines for prescribing opioid painkillers that remove its previous recommended ceilings on doses for chronic pain patients and instead encourage doctors to use their best judgment. The new guidelines were reported in today's New York Times But the overall thrust of the recommendations [...]

Selective publication of antidepressant trials and its influence on apparent efficacy: A meta-analyses 

By |2022-02-04T09:52:31-08:00February 4th, 2022|Brief Bulletins from the Field, We Know Psychiatry|

Valid assessment of drug efficacy and safety requires an evidence base free of reporting bias. Using trial reports in Food and Drug Administration (FDA) drug approval packages as a gold standard,  researchers, Turner, Cipriani, Furukawa, et al. previously found that the published literature inflated the apparent efficacy of antidepressant drugs. [...]

Psychiatric comorbidity and risk of premature mortality is significant

By |2022-02-04T09:53:19-08:00February 4th, 2022|Brief Bulletins from the Field, We Know Psychiatry|

A group of researchers aimed to determine the risks of premature mortality and suicide in people with common noncommunicable diseases, with and without psychiatric disorder comorbidity. In this longitudinal study of over 1 million patients with chronic health diseases, researchers observed increased risks of all-cause and suicide mortality in individuals [...]

IN PRESS: 52/1/2022

By |2022-02-10T07:40:30-08:00January 28th, 2022|Articles in Press, Brief Bulletins from the Field, We Know Psychiatry|

  ORIGINAL RESEARCH Doxepin for Insomnia: Executive Function before and after Treatment By Zhenghe YU, Li HAN, Pan YAN, Wenjuan LIU, Lishan REN, You XU, Lili YANG, Lisha MA, Youdan WEI, Yi LIU, Shengdong WANG DRUG DISPOSITION AND PHARMACOKINETICS Protein Biomarkers in Monocytes and CD4+ Lymphocytes for Predicting Lithium Treatment Response of [...]

Orally Dissolving Buprenorphine Tied to Severe Tooth Decay

By |2022-01-31T08:48:07-08:00January 17th, 2022|Brief Bulletins from the Field, We Know Psychiatry|

Orally dissolving medications containing buprenorphine are linked to severe dental problems, including total tooth loss, the US Food and Drug Administration (FDA) warns in a safety communication. The oral side effects of these medications, which are used to treat opioid use disorder (OUD) and pain, include cavities/tooth decay, including rampant caries; dental abscesses/infection; tooth [...]

Aaron Beck, Father of Cognitive Behavioral Therapy, Dies at 100

By |2021-11-02T10:53:15-07:00November 2nd, 2021|Brief Bulletins from the Field, We Know Psychiatry|

Aaron "Tim" Beck, MD, known as the father of cognitive behavioral therapy (CBT), died on Monday in Philadelphia. He was 100. Beck's pioneering career in psychoanalysis spanned more than seven decades, yielding more than 600 published articles and nearly two dozen books. His development of CBT redefined the practice of [...]

Go to Top